Monoclonal antibodies to target epidermal growth factor receptor-positive tumors a new paradigm for cancer therapy

Cancer

Volumn 94, Issue 5, 2002, Pages 1593-1611

  Herbst, Roy S ^a   Shin, Dong M ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

(TGF ); ABX EGF; Carcinoma; Chemotherapy; EGF receptor (EGFR); EMD 55900; Epidermal growth factor (EGF); ICR 62; IMC C225; Monoclonal antibody; Radiation therapy; Transforming growth factor

Indexed keywords

AMPHIREGULIN; ANTIBODY; ANTIHISTAMINIC AGENT; BETACELLULIN; CANERTINIB; CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; GEMCITABINE; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; IRINOTECAN; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY EMD 55900; MONOCLONAL ANTIBODY ICR 62; MONOCLONAL ANTIBODY IMC C225; PANITUMUMAB; PROTEIN TYROSINE KINASE; RETINOBLASTOMA PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ALLERGIC REACTION; ANGIOGENESIS; ARTICLE; BINDING SITE; CANCER; CANCER RADIOTHERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0036500831     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10372     Document Type: Article

References (149)

1. The genetic engineering of monoclonal antibodies
2. A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced tumor activities
3. Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response
4. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas
5. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines
6. Dose-dependent access of murine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carcinoma
7. Phase I trial and tumour localization of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer
8. Potent anti-tumor activity of ABX-EGF a fully human monoclonal antibody to epidermal growth factor receptor
9. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogenes
10. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
11. Her-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
12. Clinical significance of HER-2/neu oncogenes amplification in primary breast cancer
13. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
14. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
15. Epidermal growth factor-targeted therapy with C225 and cisplatin in patients with head and neck cancer
16. Continued response following treatment with IMC-C225, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MoAb), combined with radiation therapy (RT) in advanced head and neck malignancies
17. Receptors for epidermal growth factor and other polypeptide mitogens
18. Epidermal growth factor
19. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with Neu oncogenes
20. The type 1 (EGFR-related) family of growth factor receptors and their ligands
21. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: A mechanism for receptor transregulation
22. neu protein and EGF receptor modulates EGF receptor function
23. Epidermal growth factor-related peptides and their receptors in human malignancies
24. Receptor dimerization is not a factor in the signaling activity of a transforming variant epidermal growth factor (EGFRvIII)
25. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer
26. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII
27. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers
28. The EGF receptor: Structure, regulation and potential role in malignancy
29. The epidermal growth factor receptor as a multi-functional allosteric protein
30. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
31. Epidermal growth factor
32. Growth factor receptor tyrosine kinases
33. Untangling the ErbB signalling network
34. Anti-tumor and cell cycle responses in KB cells treated with a chimeric anti-EGFR monoclonal antibody in combination with cisplatin
35. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice
36. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
37. The biological effects of anti-epidermal growth factor receptor and ionizing radiation in human head and neck tumor cell lines
38. Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line
39. CDK inhibitors: Positive and negative regulators of G1-phase progression
40. EGF-R dependent regulation of keratinocyte survival
41. Tumour angiogenesis
42. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
43. Transforming growth factor-α-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation
44. Expression of growth factors, growth-inhibiting factors, their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis
45. Epidermal growth factor (EGF) increases the in vitro invasion, motility, adhesion interactions of the primary renal carcinoma cell line, A704
46. Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumor biopsies in vitro
47. Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth
48. In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals
49. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells
50. The EGF receptor system as a target for antitumor therapy
51. Modulation of pro-epidermal growth factor, pro-transforming growth factor α and epidermal growth factor receptor gene expression in human renal carcinomas
52. Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer
53. EGF, TGF-α, and EGF-R in human colorectal adenocarcinoma
54. Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck
55. Dysregulation of epidermal growth factor receptor expression in multistep process of head and neck tumorigenesis
56. Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer
57. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer
58. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor α is frequent in respectable non-small cell lung cancer but does not predict tumor progression
59. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small cell lung cancer: Amphiregulin and microvessel count are independent prognostic indicators of survival
60. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients
61. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas
62. Expression analyses of epidermal growth factor receptor and HER2/neu: No advantage of prediction of recurrence or survival in breast cancer patients
63. EGF-R expression in ductal breast cancer: Proliferation and prognostic implications
64. Studies of the expression of epidermal growth factor receptor in human renal cell carcinoma: A comparison of immunohistochemical method versus ligand binding assay
65. EGFR and steroid receptors in ovarian carcinoma: Comparison with prognostic parameters and outcome of patients
66. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer
67. A comparative study of epidermal growth factor receptor (EGFR) and MDM2 gene amplification and protein immunoreactivity in human glioblastomas
68. Genes for epidermal growth factor receptor, transforming growth factor α, and epidermal growth factor and their expression in human gliomas in vivo
69. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer
70. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer
71. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival
72. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma
73. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness
74. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival
75. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas
76. Evidence for a role of EGF receptor in the progression of human lung carcinoma
77. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study
78. Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors
79. Impact of the expression of epidermal growth factor, transforming growth factor alpha, and epidermal growth factor receptor on the prognosis of superficial bladder cancer
80. The epidermal growth factor receptor and the prognosis of bladder cancer
81. Expression of metastasis-related genes in surgical specimens of human gastric cancer can predict disease recurrence
82. Increased estrogen receptor and epidermal growth factor receptor gene product co-expression in surgically resected gastric adenocarcinomas
83. Occurrence of epidermal growth factor receptors in human adnexal tumors and their prognostic value in advanced ovarian carcinomas
84. Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients
85. Detection of epidermal growth factor receptor gene amplification in human squamous cell carcinomas using fluorescence in situ hybridization
86. Patterns of epidermal growth factor receptor amplification in malignant gliomas
87. Gene amplification in human gliomas
88. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells
89. Differential expression of epidermal growth factor receptor in human head and neck cancers
90. C-erbB2 amplification and overexpression in human tumors
91. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: A study in Greek patients
92. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer
93. Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation
94. EGFR blockade by tyrosine kinase inhibitor or monoclonal anti-body inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5
95. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin
96. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diammine-dichloroplatinum on well established A431 cell xenografts
97. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells
98. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter
99. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis
100. Cytotoxic activity of epidermal growth factor-Genistein against breast cancer cells
101. Neutralizing antibodies against epidermal growth factor and ErB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
102. Chimeric monoclonal antibody (Mab) C225 to the epidermal growth factor receptor (EGF-R) antibody inhibits angiogenesis in human transitional cell carcinoma (TCC)
103. Inhibition of murine bladder tumorigenesis by soy isoflavone via alterations in the cell cycle, apoptosis, and angiogenesis
104. Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD 166285 and PD173074: Implications for combination treatment with photodynamic therapy
105. Protein factors which regulate cell motility
106. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor α in the progression of prostatic neoplasms
107. Ligand-induced activation of A431 cell EGF receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly
108. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily. Role as anticancer agents
109. Treatment of cancer with radiation and drugs
110. A pilot trial demonstrates the safety of ZD-1839 ('Iressa'), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer
111. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
112. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity
113. Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma in A431 cells
114. Growth stimulation of A431 cells by epidermal growth factor: Identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody
115. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors
116. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma
117. Phase I and imaging trial of indium-111 labeled anti-EGF receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma
118. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
119. 1 arrest in prostatic cancer cell line DU145
120. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice
121. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
122. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
123. Potentiation of antitumor activity of PG-TXL with anti-EGFR monoclonal antibody C225 in MDA-MB-468 human breast cancer xenograft
124. A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo
125. Potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (IRESSA), and EGFR-selective tyrosine kinase inhibitor
126. ZD1839 ('IRESSA'), a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): Inhibition of c-fos mRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition
127. Combining radiation with molecular blockade of the EGF receptor in cancer therapy
128. Treatment of human intracranial gliomas with chimeric monoclonal antibody against the epidermal growth factor receptor increases survival of nude mice when treated concurrently with irradiation
129. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
130. Potentiation of radiation-induced breast cancer cell death by inhibition of epidermal growth factor family of receptors
131. Apoptosis in the pathogenesis and treatment of disease
132. Biological modifiers as potential radiosensitizers: Targeting the epidermal growth factor receptor family
133. Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells
134. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer
135. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
136. C225 anti-EGFR antibody potentiates radiation (RT) and chemotherapy (CT) cytotoxicity in human non-small cell lung cancer (NSCLC) cells in vitro and in vivo
137. Phase I trial of chimerized anti-epidermal growth factor receptor (EGFR) antibody in combination with either once-daily or twice-daily irradiation for locally advanced head and neck malignancies
138. Concomitant radiotherapy with mitomycin C and bleomycin compared with radiotherapy alone in inoperable head and neck cancer: Final report
139. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer
140. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomized trial
141. Efficacy and safety of the anti-epidermal growth factor antibody (EGFR) IMC-C225 in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy
142. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer
143. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
144. Safety profile of the monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFR) used in the treatment of EGFR-positive tumors
145. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy
146. Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55 900) in patients with recurrent malignant gliomas